Abstract
A 25-year-old female presented with an extensive ulceration of the left upper and lower eyelids (Fig. 40.1). Generally, she had pallor, fatigue and malaise. Her medical history was positive for autoimmune hepatitis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsBibliography
Balduini CL, Guarnone R, Pecci A, Centenara E, Rosangela I, Ascari E. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica. 1999;84(12):16.
Besa EC. Myelodysplastic syndromes (refractory anemia). A perspective of the biologic, clinical, and therapeutic issues. Med Clin North Am. 1992;76(3):599–617.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.
Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol. 1987;87:180–6.
Goldberg H, Lusk E, Moore J, Nowell PC, Besa EC. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome: correlation with chromosome patterns and data on patients without hematological disease. Cancer Res. 1990;50(21):6876–81.
List AF, Garewal HS, Sandberg AA. The myelodysplastic syndromes, biology and implications for management. J Clin Oncol. 1990;8:1424–41.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–65.
Lübbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol. 2001;114(2):349–57.
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42.
Maschek H, Georgii A, Kaloutal V, et al. Myelofibrosis in primary myelodysplastic syndromes. A retrospective study of 352 patients. Eur J Haematol. 1992;48:208–14.
Mathew P, Tefferi A, Dewald GW, Goldberg SL, Hoagland HC, Noel P. The 5q-syndrome. A single institution study of 43 consecutive cases. Blood. 1993;81:1040–5.
Orazi A, Albitar M, Heerema NA, Haskins NS, Neiman RS. Hypoplastic myelodysplastic syndrome can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107:268–74.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, Diez JL, Bureo E, Marqués ML, Arranz E, Ríos R, Martínez Climent JA, Vallespí T, Florensa L, Woessner S. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108(2):346–56. doi:2.
Tricot G, Vlietnick R, Boogaerts MA, Hendrickx B, De-Wolf-Peeters C, Van den Berghe H, et al. Prognostic factors in the myelodysplastic syndromes. Importance of initial data on peripheral blood counts, bone marrow, cytology, trephine biopsy and chromosomal analysis. Br J Haematol. 1985;60:19–32.
Vardiman JW. Myelodysplastic/myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001a.
Vardiman JW, Pierre R, Imbert M, Bain B, Brunning RD, Flandrin G. Juvenile myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001b.
Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956–62.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
El-Darouti, M.A. (2013). Unexplained Anemia with Pyoderma Gangrenosum-Like Ulcer. In: Challenging Cases in Dermatology. Springer, London. https://doi.org/10.1007/978-1-4471-4249-2_40
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4249-2_40
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4248-5
Online ISBN: 978-1-4471-4249-2
eBook Packages: MedicineMedicine (R0)